✦ LIBER ✦

Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403)

✍ Scribed by Tamura, K; Okamoto, I; Kashii, T; Negoro, S; Hirashima, T; Kudoh, S; Ichinose, Y; Ebi, N; Shibata, K; Nishimura, T

Book ID: 109999424
Publisher: Nature Publishing Group
Year: 2008
Tongue: English
Weight: 142 KB
Volume: 98
Category: Article
ISSN: 0007-0920
DOI: 10.1038/sj.bjc.6604249

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase I/II study of carboplatin plus g

A phase I/II study of carboplatin plus gemcitabine for elderly patients with advanced non-small cell lung cancer: West Japan Thoracic Oncology Group Trial (WJTOG) 2905

✍ Kurata, Takayasu; Hirashima, Tomonori; Iwamoto, Yasuo; Kawaguchi, Tomoya; Ikeda, 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 232 KB

Prospective Phase II Study of Gefitinib

Prospective Phase II Study of Gefitinib for Chemotherapy-Naive Patients With Advanced Non-Small-Cell Lung Cancer With Epidermal Growth Factor Receptor Gene Mutations

✍ Inoue, A. 📂 Article 📅 2006 🏛 American Society of Clinical Oncology 🌐 English ⚖ 262 KB

Gefitinib versus cisplatin plus docetaxe

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

✍ Tetsuya Mitsudomi; Satoshi Morita; Yasushi Yatabe; Shunichi Negoro; Isamu Okamot 📂 Article 📅 2010 🏛 The Lancet 🌐 English ⚖ 239 KB

Gefitinib versus cisplatin plus docetaxe

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

✍ Tetsuya Mitsudomi; Satoshi Morita; Yasushi Yatabe; Shunichi Negoro; Isamu Okamot 📂 Article 📅 2010 🏛 The Lancet 🌐 English ⚖ 239 KB

Background Patients with non-small-cell lung cancer harbouring mutations in the epidermal growth factor receptor (EGFR) gene respond well to the EGFR-specific tyrosine kinase inhibitor gefitinib. However, whether gefitinib is better than standard platinum doublet chemotherapy in patients selected by

O-092 Randomized phase III study of doce

O-092 Randomized phase III study of docetaxel (D) versus vinorelbine (V) for elderly patients (pts) with advanced non-small cell lung cancer (NSCLC): Results of a West Japan Thoracic Oncology Group trial (WJTOG9904)

✍ Tamura, K.; Kudoh, S.; Negoro, S.; Nakagawa, K.; Takada, M.; Katakami, N.; Matsu 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 140 KB

Prospective Study of Gefitinib in Epider

Prospective Study of Gefitinib in Epidermal Growth Factor Receptor Fluorescence In Situ Hybridization-Positive/Phospho-Akt-Positive or Never Smoker Patients With Advanced Non-Small-Cell Lung Cancer: The ONCOBELL Trial

✍ Cappuzzo, F.; Ligorio, C.; Janne, P. A.; Toschi, L.; Rossi, E.; Trisolini, R.; P 📂 Article 📅 2007 🏛 American Society of Clinical Oncology 🌐 English ⚖ 130 KB